Nutra Pharma

Founded in 2000, Nutra Pharma Corp. (OTC: NPHC) is a biotechnology company with a dual mission: to develop innovative, non-opioid therapeutics from its proprietary cobra venom toxin platform and to commercialize accessible pain management products. Its strategy hinges on acquiring, licensing, and commercializing pharmaceutical assets for complex conditions like multiple sclerosis and HIV, while generating near-term revenue through direct-to-consumer sales of its OTC pain relievers. The company's core scientific achievement is over a decade of peer-reviewed research validating the anti-inflammatory, immunosuppressive, and analgesic properties of its lead compound, alpha-cobratoxin.

A proprietary therapeutic platform based on alpha-cobratoxin and related neurotoxins derived from cobra venom, exhibiting multi-target mechanisms including opioid-independent analgesia, potent immunosuppression, and anti-inflammatory effects.

In pharmaceuticals, Nutra Pharma competes from a resource-disadvantaged, preclinical position against giants in MS, pain, and infectious diseases. In OTC pain relief, it faces intense competition from entrenched consumer brands and a crowded field of natural remedies, requiring significant marketing investment for differentiation.